Adamax

🔬Kas yra Adamax

Adamax is an adamantane-modified analogue of Semax (a synthetic ACTH(4-7)-derived nootropic peptide) engineered with an adamantyl group to dramatically increase blood-brain barrier penetration, metabolic stability, and receptor affinity. Preclinical research indicates that the adamantane modification allows Adamax to remain active in the CNS significantly longer than native Semax, while retaining the same core mechanism: upregulation of BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), modulation of dopaminergic and serotonergic pathways, and pronounced neuroprotection against ischemic and oxidative stress. It is being investigated as one of the most potent and stable nootropic peptides in the Semax family.

📊Klinikiniai tyrimai ir rezultatai

Adamax builds on decades of Semax research, with additional preclinical work focused on its adamantane-enhanced pharmacokinetics:

• ▪Adamantane modification of Semax analogues significantly extended CNS half-life and enhanced BBB permeability in rodent pharmacokinetic studies
• ▪Retained the BDNF/NGF-upregulating profile of the parent Semax peptide (ACTH(4-7) fragment family)
• ▪Demonstrated neuroprotection in cerebral ischemia-reperfusion models comparable to or exceeding classic Semax
• ▪Modulated dopaminergic and serotonergic neurotransmission without tolerance development over extended administration periods

Adamax is positioned as one of the most stable and potent members of the Semax nootropic peptide family under active research.

🏆Privalumai

• Substantially enhanced BBB penetration versus classic Semax
• Longer half-life and sustained cognitive effects per dose
• Upregulates BDNF and NGF for lasting neuroplasticity
• Powerful neuroprotection against ischemic and oxidative stress
• Supports memory, focus and executive function
• No tolerance build-up or stimulant-like crash reported

⚠️Galimas šalutinis poveikis

• ▪Very well tolerated with minimal adverse effects in preclinical research
• ▪No psychostimulant-like side effects (no jitteriness, insomnia, or crash)
• ▪No addiction potential or withdrawal effects reported
• ▪Rare mild headache during initial administration period
• ▪No significant hormonal or metabolic disruption documented
• ▪Compatible with most other nootropic and neuroprotective compounds

🎯Idealiai tinka

• →Advanced nootropic and focus research
• →Neuroprotection and post-ischemic recovery studies
• →Age-related cognitive decline protocols
• →Long-acting alternative to standard Semax
• →Stacking with Selank for balanced anxiolytic-nootropic profiles